JCR Pharmaceuticals - Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation

Published July 23, 2026 at 1:57 p.m. UTC

Source: MarketScreener

Hyogo, Japan - JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR') announces the completion of payment procedures for the disposition of treasury stock as restricted stock compensation, in accordance with the resolution at the meeting of the Board of Directors on June 23, 2026.

For more details, please refer to the 'Notice Regarding the Disposition of Treasury Stock as Restricted Stock Compensation' on June 23, 2026.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values - Putting people first, Forging our own path, Always advancing, and Committed to excellence - mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level.

Contact:

Email: [email protected]